SynthesisFrontiers in endocrinology2026
The diagnostic value of immune-inflammatory markers for diabetic kidney disease in type 2 diabetic patients: a meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic kidney disease (DKD) constitutes a chronic renal condition arising from type 2 diabetes mellitus after excluding other causes. Immune-inflammatory responses are pivotal in the pathogenesis of DKD, and related biomarkers may be diagnostic targets. Methods: The current meta-analysis appraises the diagnostic value of common immune-inflammatory indicators-red blood cell distribution width (RDW), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), and systemic inflammation response index (SIRI)-for early and established DKD. Results: We systematically retrieved the Cochrane Library, Embase, PubMed, Web of Science, CNKI, CBM, VIP, and Wanfang databases up to October 11, 2025. The QUADAS-2 tool was applied to evaluate study quality. Meta-analyses were implemented employing Stata 16.0, RevMan 5.3, and MetaDisc 1.4. Conclusion: Thirty-two eligible investigations were incorporated: 11 on early DKD(649 subjects) and 21 on DKD(9,120 subjects). The meta-analysis yielded pooled diagnostic performance metrics. For early DKD, PLR showed a sensitivity of 0.74 (95% CI: 0.65-0.81), specificity of 0.69(0.54-0.81), and AUC of 0.78(0.74-0.81). For established DKD, SII demonstrated a sensitivity of 0.68(0.59-0.75), specificity of 0.64 (0.54-0.72), and an AUC of 0.71(0.67-0.74). PLR, MLR, MPV, and RDW exhibited low to moderate diagnostic accuracy for both stages (AUC range: 0.68-0.74). Common immune-inflammatory markers have diagnostic value for early and established DKD. Among them, PLR offers moderate diagnostic accuracy for early DKD, while SII performs relatively better for diagnosing DKD. These findings should be verified through future high-quality studies due to limitations of eligible research. Systematic review registration: https://www.crd.york.ac.uk/prospero/, Identifier CRD420251174942.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.